Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07100483

Comparing Surgical Management Methods of Atrial Fibrillation

Compare the efficacy of the left atrial Cox-Maze IV lesion set versus the Tampa 2 lesion set versus the EnCompass ablation alone, in the surgical treatment of atrial fibrillation at one year post-operatively.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Corewell Health West

Grand Rapids, Michigan, 49503, United States

About this study

This is a single center prospective, randomized trial to compare the outcomes, specifically the freedom from atrial fibrillation at one year, and possibly up to five years, of three different approaches to the cardiac surgical management of atrial fibrillation.

Several strategies to accomplish surgical ablation are acceptable and have been shown retrospectively to be successful. The Cox-Maze bi-atrial, left and right atrial lesions, ablation (whether III or IV) remains the gold standard by which all surgical ablations are compared. Further refinement in ablation technology and research has further suggested there is no difference between a left atrial ablation alone or bi-atrial ablation lesion set. For left atrial ablation alone, existent therapeutic options, which all meet equivalent standard of care, include a left atrial Cox-Maze IV , a Tampa 2 lesion set or utilizing a "box lesion" alone. Currently, there are no randomized, clinical trials demonstrating better efficacy (freedom from atrial fibrillation post-operatively) of one ablation strategy over another in patients undergoing cardiac surgery.

The rationale for the study is to demonstrate whether one ablation technique is more efficacious in the surgical treatment of AF. Should one technique prove superior it may clarify the question of which ablation strategy to utilize and encourage surgeons to implement a consistent approach to surgical ablation.

To our knowledge this study would be the first prospective, randomized trial in the United States comparing surgical lesion sets in the concomitant management of atrial fibrillation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients with a history of preoperative atrial fibrillation, either paroxysmal or persistent, requiring concomitant surgical ablation who are scheduled to undergo cardiac surgical procedure(s) to be performed on cardiopulmonary bypass
  • Utilizing sternotomy approach requiring cardiopulmonary bypass
  • Male or Female subjects between age 18 to 85 years of age

Exclusion criteria

  • LVEF < 25%
  • LAVI > 59ml/m②
  • Presence of Pacemaker/AICD
  • History of VT/VF, WPW
  • Re-operative cardiac surgery

Treatment and study plan

Atrial fibrillation ablation

Procedure

Ablation of the heart to reduce Afib Occurrence

Primary outcomes

  1. Freedom from Atrial Fibrillation

    Time frame: 30 days and 1 year

    Freedom from atrial fibrillation at 30 days and one year

Secondary outcomes

  1. Prescribed Antiarrhythmic and anticoagulant drugs

    Time frame: 7 days and 1 year

    Antiarrhythmic and anticoagulant drugs at 7days and one year post surgery

Sponsors and collaborators

Lead sponsor

Corewell Health West

Other

Registry information

Official study title

Prospective, Randomized Trial Comparing Left Atrial Cox-Maze IV, Tampa 2 or Encompass Alone, Ablation in the Surgical Management of Atrial Fibrillation

Important dates

Study start
2025
Primary completion
2027
Study completion
2032
First posted
Aug 3, 2025
Registry last updated
Jul 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.